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Nucleic  acid  ampliﬁcation  techniques  have  become  the mainstay  for ultimate  sensitivity  for  detecting
low  levels  of virus,  including  human  immunodeﬁciency  virus  (HIV).  As  a  sophisticated  technology  with
relative  expensive  reagents  and  instrumentation,  adoption  of  nucleic  acid  testing  (NAT)  can  be cost
inhibited  in  settings  in  which  access  to  extreme  sensitivity  could  be  clinically  advantageous  for  detection
of  acute  infection.  A simple  low  cost  digital  immunoassay  was  developed  for  the  p24 capsid  protein  of  HIV
based  on  trapping  enzyme-labeled  immunocomplexes  in  high-density  arrays  of  femtoliter  microwells
and  constraining  the  diffusion  of  the  enzyme–substrate  reaction.  The  digital  immunoassay  was  evalu-
ated  for  analytical  sensitivity  for  HIV capsid  protein  p24,  and  compared  with  commercially  available  NAT
methods  and  immunoassays  for  p24,  including  4th-generation  antibody/antigen  combo  assays,  for  early
detection of HIV  in  infected  individuals.  The  digital  immunoassay  was  found  to exhibit  2000–3000-fold
greater  analytical  sensitivity  than  conventional  immunoassays  reactive  for  p24,  and  comparable  sensitiv-
ity to NAT  methods.  Assaying  serial  samples  from  10  HIV-infected  individuals,  the  digital  immunoassay
detected  acute  HIV infection  as  early  as NAT  methods,  and  7–10  days  earlier  than  conventional  immunoas-
says.  Comparison  of  assay  results  between  the  digital  immunoassay  and  a quantitative  NAT  method
from  HIV infected  serum  exhibited  a linear  correlation  R2 >  0.99. The  data  indicate  that  by constraining
diffusion  of  the  signal  generation  step  of  a  simple  sandwich  immunoassay  and  enabling  the  digital  count-
ing  of immunocomplexes,  dramatic  improvements  in sensitivity  to virus  can  be obtained  to  match  the
sensitivity  of  NAT at a fraction  of  the  cost.
© 2012 Elsevier B.V. Open access under CC BY-NC-ND license.. Introduction
Since the development of the polymerase chain reaction in
he 1980s (Mullis et al., 1986), ampliﬁcation of speciﬁc nucleic
cid sequences for genetic identiﬁcation has become an indis-
ensible tool in medical research and diagnostics, including the
etection and diagnosis of infectious disease. With its imple-
entation for blood screening in the US in 1999 (Busch et al.,
000), nucleic acid ampliﬁcation testing (NAT) for detection of
iral pathogens has helped safeguard blood for transfusion by
roviding the most sensitive, economically feasible detection of
nfected blood donations possible. For HIV detection, NAT meth-
ds in use for blood screening are capable of analytical sensitivities
f approximately 60 HIV RNA copies/mL (30 viruses/mL) with indi-
idual donors (Assal et al., 2009; Proceix ULTRIO Product Insert,
011). In the clinical setting, NAT is the gold standard for high
∗ Corresponding author.
E-mail address: dwilson@quanterix.com (D.H. Wilson).
166-0934 ©  2012 Elsevier B.V. 
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Open access under CC BY-NC-ND license.sensitivity detection of acute HIV infection. NAT has signiﬁcantly
shortened the window between initial infection and its detection
through ampliﬁcation of viral nucleic acid rather than detecting
the presence of antibody following seroconversion (Busch, 2007).
Although NAT has become the mainstay for detection of viruses,
the technology is relatively complex and high cost (Westreich et al.,
2008), and can be cost inhibitory or prohibitive in settings where
access to high sensitivity could be clinically advantageous. These
scenarios include blood donor screening in lower-resource settings
and clinical screening in higher incidence areas, where a signiﬁcant
number of cases of acute infection can be missed by less sensi-
tive immunoassay tests. Rapid detection and reporting of acute HIV
infection represents a key opportunity to control the march of the
disease because viral transmission is 10 times more likely during
the acute phase than in the chronic phase (Wawer  et al., 2005).
Immunoassays, on the other hand, are simpler and lower
cost than NAT, and can be deployed in more diverse environ-
ments. Conveniently, nature provides its own  ampliﬁcation of
protein molecules from each virus in the form of antibodies to the
virus and the viral proteins. Immunoassays to HIV antibodies are
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traightforward, but they require the immune response and are
nable to detect acute infection when antibodies are not yet
resent. 3rd generation antibody assays (Constantine et al., 1994)
etect the earliest stage of the immune response (immunoglobu-
in M),  reducing the serological window to approximately 3 weeks
Fiebig et al., 2003). Viral proteins are present at the start of infec-
ion, and each HIV particle produces approximately 2000 copies
f p24 capsid protein (NIAID, 2011), which works in favor of
mmunoassay detection of acute infection. 30 viruses/mL equates
o approximately 60,000 p24 molecules per mL,  or a concentration
f 3 fg/mL. Unfortunately, current, state-of-the-art conventional
mmunoassays are not sufﬁciently sensitive to detect these low
umbers. Immunoassays for p24 (Kontio, 1991) and 4th genera-
ion combo assays that combine reactivity for p24 and anti-HIV
ntibodies (Weber et al., 1998) can only detect the presence
f circulating p24 antigen after it has elevated to greater than
1,000–70,000 fg/mL (Marcel et al., 2011). While this can reduce
he detection window another 4 or 5 days relative to serology
ests, immunoassays for p24 remain thousands-fold less sensi-
ive for virus than HIV RNA detection, which reduces the window
n additional week or more relative to antigen detection (Fiebig
t al., 2003). Thus conventional immunoassays remain blind to
ost of the acute phase window that is detectable by NAT. A simple
mmunoassay capable of the sensitivity of NAT for HIV could repre-
ent another step forward in broader, more cost effective detection
f acute HIV infection, which would help further control the spread
f the disease.
Thermodynamically, antigen–antibody interactions should
nable sufﬁcient sensitivity for detection of fg/mL concentrations
f antigen with little ampliﬁcation. The problem for unampliﬁed
ethods has been acquiring sufﬁcient signal of this interaction.
onventional immunoassays employing optical signal detection
such as chemiluminescence) require millions to thousands of
illions of signal molecule events before signal can be reliably
iscerned by a luminometer or ﬂuorometer. This limitation arises
ecause the ensemble signal is diluted in a typical reaction vol-
me  of hundreds of microliters required for measurement. When
he signal molecules are constrained from diffusing beyond a small
ocal volume, then lower numbers of signal molecules would be suf-
cient for optical detection due to their local high concentration.
ith an isolated enzyme-labeled antigen, the smaller the volume of
onﬁnement, the higher the local concentration of signal molecules
or detection. By conﬁning enzyme labels within femtoliter vol-
mes, single molecules are readily detectable by a low cost CCD
amera (Rissin et al., 2010). This simple concept is used to power a
tandard sandwich immunoassay for p24 antigen to NAT-level sen-
itivity for detection of acute HIV infection. The sensitivity of the
mmunoassay is demonstrated by comparison to NAT and 4th gen-
ration immunoassay with serial seroconversion sample sets from
IV infected individuals. The assay is standardized to quantitate
24 protein, and correlation between p24 concentration and viral
NA copies/mL by quantitative NAT is shown with HIV infected
erum. The data suggest that low cost digital immunoassay technol-
gy could have important implications for HIV screening efﬁcacy
nd economics.
. Materials and methods
.1. Recombinant p24
The recombinant p24 was obtained from Novartis Vaccines &
iagnostics (Emoryville, CA). The HIV-1 p24 antigen is a polypep-
ide encoded by the p24 gag region (Steimer et al., 1986) of the
IV-1 SF2 genome (Sanchez-Pescador et al., 1985) (231 amino
cids; HIV-1 amino acid residues 139–369) and is produced inMethods 188 (2013) 153– 160
genetically engineered Saccharomyces cerevisiae.  One amino acid
(met) was  inserted at the N-terminus to enable expression.
2.2. Cultured virus
The cultured HIV-1 Group M,  Subtype B virus was purchased
from Seracare Life Sciences (Part number PN242B, lot 9899P-10,
1.15 × 109 HIV-1 RNA/mL by Roche AMPLICOR® HIV-1 MonitorTM
Assay, v. 1.5) and diluted in delipidated, deﬁbrinated human
serum (Seracare PN: HS-210). This virus is harvested from the
culture supernatant without additional puriﬁcation; therefore the
standard could contain free p24 in addition to virion-incorporated
p24. The diluted virus, at 1 × 107 copies HIV-1 RNA/mL, was inactiv-
ated by the addition of Triton X-100 to 0.4% and incubation of the
sample for 1 h at 37 ◦C (Ukkonen et al., 1988).
2.3. Seroconversion panels
Sets of seroconversion serum samples from HIV infected indi-
viduals were purchased from SeraCare (PRB956, PRB958, PRB967,
RB968, PRB969, PRB972) and from Zeptometrix (ZM-HIV9016, ZM-
HIV9018, ZM-HIV9024, ZM-HIV9031).
2.4. Digital immunoassay
Digitization of immunoassay analyte detection using single
molecule arrays (Simoa®) has been described (Rissin et al., 2010,
2011). In brief, it involves performing a standard paramagnetic
microbead-based enzyme-linked immunosorbent assay (ELISA),
singulation of individual microbeads in high-density arrays of 50 fL
microwells, and conﬁnement within the microwells of ﬂuorescent
product generated by enzymes labeling the immunocomplexes.
Preventing diffusion of the ﬂuorescent product out of the wells per-
mits rapid buildup of ﬂuorescence that is readily visualized with a
CCD camera. Immunocomplexes are labeled with -galactosidase
(G) during the ELISA, and 30 s of conversion of enzyme substrate
(resoruﬁn -d-galactopyranoside, RGP) into ﬂuorescent product
(resoruﬁn) by a single molecule of G provides sufﬁcient signal
to differentiate wells containing beads with an enzyme label from
wells containing beads without an enzyme. At very low p24 con-
centrations, Poisson statistics predict that bead-containing wells
in the array will contain either a single labeled p24 molecule or no
p24 molecules, resulting in a digital signal of either “active” (posi-
tive) or “inactive” (negative) wells (Rissin and Walt, 2006). Positive
wells are counted and averaged for each array to give ‘average
enzymes per bead’ (AEB), which represents the fundamental mea-
surement unit for Simoa. At higher p24 concentrations, when all
wells become occupied by at least one labeled p24 molecule, dig-
ital measurements transition to conventional non-digital (analog)
measurements of total ﬂuorescence intensity. These analog mea-
surements are converted into AEB based on the known average
ﬂuorescence intensity generated by single enzymes, as determined
by digital measurements made at low p24 concentrations. With
single-molecule sensitivity, concentrations of labeling reagents can
be lowered, resulting in reduced nonspeciﬁc background. This
enables high signal-to-background ratios at extremely low ana-
lyte concentrations. Because large numbers of positive wells can
be simultaneously counted on a single array, lengthy sequen-
tial bead counting is not needed for statistically powered data.
This approach makes Simoa digital immunoassays compatible
with the fast processing cadence of a high throughput automated
immunoassay analyzer. The immunoassay described in this report
utilizes standard low-cost reagents to demonstrate that a short
diffusion-constrained signal ampliﬁcation step enables thousands-
fold greater sensitivity for p24 than conventional immunoassays.
Together with nature’s ampliﬁcation of 2000 p24 molecules per
gical Methods 188 (2013) 153– 160 155
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Fig. 1. Dose–response of digital immunoassay over three logs of spiked p24 in
human plasma. Y-Axis refers to the average number of label enzymes per individ-
ual  microbead (AEB) captured in each well of the array. Each data point depicts the
mean of three replicates. Standard deviations for each set of replicates are within the
circles. (a) Log-log representation of the data with 0 pg/mL calibrator omitted. (b)
Non-log depiction of the 0–0.1 pg/mL range (0 pg/mL calibrator included) showing
the  low background obtained with digital quantiﬁcation. Analyses of 11 calibrationL. Chang et al. / Journal of Virolo
IV, this simple immunoassay can detect less than 100 viruses/mL,
omparable to the sensitivity of NAT for detection of acute HIV
nfection.
.5. Digital immunoassay reagents
Three reagents were developed: paramagnetic p24 cap-
ure microbeads, biotinylated detector, and a streptavidin:-
alactosidase (SG) conjugate. The capture beads were comprised
f a monoclonal anti-p24 antibody (Capricorn HIV-018-08204),
ovalently attached by standard coupling chemistry to 2.7 m
arboxy paramagnetic microbeads (Varian). The antibody-coated
eads were diluted to a concentration of 5 × 106 beads/mL in PBS
uffer with a surfactant and BSA. Biotinylated detector reagent
as comprised of a second monoclonal anti p24 antibody (Zep-
ometrix 801136), which was biotinylated using standard methods
nd diluted to a concentration of 0.2 g/mL in a PBS diluent con-
aining a surfactant and goat serum, GS (PBS/GS). SG was prepared
y covalent conjugation of puriﬁed streptavidin (Thermo Scien-
iﬁc) and G (Sigma) using standard coupling chemistry. For assay,
liquots of a concentrated SG stock were diluted to 15 pM in
BS/NCS with 1 mM  MgCl2.
.6. Calibration
The assay was calibrated using recombinant p24 protein diluted
n pooled human serum (Seracare HS210). Calibrator levels were 0,
.001, 0.010, 0.022, 0.100, 1.000 and 10.00 pg/mL.
.7. Immunoassay procedure
Bead-sample incubations and labeling of immunocomplexes
ere conducted as described (Rissin et al., 2010), except that sam-
les were assayed without pre-dilution. In brief, the prototype
igital p24 assay requires 100 L of sample and was  performed
n three steps: analyte capture with 500,000 anti-p24 coated
icrobeads for 120 min, biotinylated detector antibody binding
or 60 min, and labeling with SG for 30 min. Assays were run in
onical 96-well ELISA plates (Axygen) using a Tecan EVO 150 for
uidics handling and bead washing between assay steps. Serum
amples were tested with no sample pretreatment. Following assay
nd bead collection with a magnet, beads were loaded onto the
rrays for imaging in a loading buffer comprised of PBS and 0.01%
ween-20, MgCl2, and sucrose.
.8. Array imaging
Beads from the ELISA were loaded onto the arrays as described
Rissin et al., 2010). Wells containing beads with labeled p24 were
isualized by the hydrolysis of enzyme substrate (RGP, Invitro-
en) by G into ﬂuorescent product. Enzyme-containing wells were
maged by ﬂuorescence microscope ﬁtted with a CCD camera. The
mages were analyzed to determine AEB as described (Rissin et al.,
011). At <70% active beads relative to total beads (low p24), the
ignal output is a count of active beads corrected for a low sta-
istical probability of multiple enzymes/bead (Rissin and Walt,
006). At >70% active beads (higher p24), the probability of multiple
nzymes/bead increases, and average ﬂuorescence of the wells is
onverted to AEB based on the average intensities of wells contain-
ng single enzymes determined at lower concentrations. The AEB
nit thus works continuously across the digital and analog realms
Rissin et al., 2011).curves gave a mean signal:background ratio at 0.01 pg/mL of 2.00. Statistics depict
least squares ﬁt of all calibrators (R2 > 0.999). LoD was estimated as 2.8 fg/mL as
described in the text.
2.9. Conversion between p24 units and RNA copies/mL
Estimates on the number of p24 units composing the HIV capsid
have ranged from ∼1000 to 3000 (Briggs et al., 2004; Summers et al.,
1992). We  used an assumption of 2000 p24 units/virion, per Piatak
et al. (1993) and accepted by National Institute of Allergy and Infec-
tious Disease (NIAID, 2011). HIV contains 2 copies of RNA/virion.
3. Results
3.1. Dose–response and limit of detection
A digital ELISA for p24 utilizing commercially available antibod-
ies and recombinant p24 for calibration was developed as described
previously for other proteins (Rissin et al., 2010; Wilson et al., 2011;
Zetterberg et al., 2011). A representative dose–response over three
logs of spiked recombinant p24 in human serum is depicted in
Fig. 1. The assay demonstrated a highly linear response, with least
squares R2 > 0.999. In a study of 11 calibration curves on differ-
ent days, the mean signal:background ratio (as AEB) at 0.01 pg/mL
was 2.00 (SD 0.35). The analytical limit of detection (LoD) was esti-
mated by reading the p24 concentration from the calibration curve
at the AEB signal corresponding to 3SD above the mean signal of
zero calibrator (n = 3). LoD was  calculated for each of 11 calibration
runs from triplicate measurements of the zero calibrator and the
lowest p24-containing calibrator (0.01 pg/mL). The mean LoD was
4.87 fg/mL (SD 2.89 fg/mL) (Fig. 2). Day-to-day reproducibility of a
Simoa digital ELISA has recently been described in detail (Wilson
et al., 2011).
3.2. Cultured standardized virus vs. recombinant p24Cultured HIV-1 Group M,  Subtype B virus was  standardized for
RNA copies/mL and diluted in human serum as described in Section
2. Fig. 3 depicts a log-log representation of assay dose–response to
156 L. Chang et al. / Journal of Virological Methods 188 (2013) 153– 160
Fig. 2. Analytical LoD estimate for the digital immunoassay. A mean LoD of
4.87 fg/mL (SD 2.89) was estimated from each of 11 calibration runs performed
on different days. For comparison, LoD ranges for p24-reactive conventional
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T
E
<mmunoassays are depicted (11,000–70,000 fg/mL Biomerieux VIDAS p24 II, VIDAS
UO Ultra, Abbott AxSYM HIV Combo, ARCHITECT HIV Combo) along with the LoD
f  the PROCLEIX system (60 RNA copies/mL).
ultured virus, and Fig. 3a highlights the low-end data down to
irus-free serum in non-log space. Calculated analytical sensitivity
as equivalent to 90 RNA copies/mL (or 45 viruses/mL), consistent
ith estimates using spiked p24 antigen. Antigen from both sources
xhibited good agreement using an equivalency conversion based
n 2000 p24 molecules per virus (Fig. 3b), in agreement with the
toichiometry accepted by the National Institute of Allergies and
nfectious Disease (NIAID, 2011).
.3. Detection of acute HIV infectionThe sensitivity of the digital immunoassay for detection of
cute HIV infection was examined with 10 sets of seroconversion
erum samples obtained from commercial sources. Table 1 depicts a
able 1
arliest detection of HIV infection.
HIV infected donor Seroconversion
sample designation
Days since
ﬁrst draw
Digital p24
immunoassay
fg/mL
1
9016-07 23 <LOD 
9016-08 27 1127.4 
9016-09 30 14089.9 
2
9018-06 19 <LOD 
9018-07 22 45.8 
9018-08 26 5067.3 
9018-09 29 52692.4 
3
9024-10 46 <LOD 
9024-11 50 1743.7 
9024-12 54 Not tested 
4
9031-13 126 <LOD 
9031-14 130 13.7 
9031-16 137 1516.5 
9031-18 152 Not tested 
Mean  days 57.3 
LOD and <50 indicate below analytical detection limits.in  non-log space. Estimated LoD was 90 copies/mL (3.6 fg/mL p24 equivalents). (b)
depicts data from a separate study comparing cultured virus (open circles) and p24
antigen (closed circles).
comparison between digital immunoassay results with a quan-
titative bDNA NAT method, an immunoassay for p24, and two
4th generation HIV combo immunoassays with four sets of late-
emerging seroconversion samples from HIV infected individuals.
The data shown for the comparator methods were obtained from
the sample vendor. Red represents the point in time at which the
assays ﬁrst detected the HIV infection. The digital immunoassay
detected the presence of p24 protein on the same blood draws that
the NAT method detected the presence of ampliﬁed HIV RNA. On
the other hand, the conventional immunoassays reactive for p24
did not detect the presence of antigen until one to four blood draws
later (average of 7–9 days). With seroconversion panel 9031, the
Abbott tests exhibited reactivity at draw #17 (3 draws, 15 days
later, not depicted) and the Coulter p24 assay exhibited ﬁrst reac-
tivity at draw #18 (4 draws, 22 days later). Noteworthy is that
seroconversion panel 9031 comprised more frequent blood draws,
and the initial reactive draw was  early in the NAT-detectable phase
Zeptometrix data
Chiron bDNA
copies RNA/mL
Coulter p24
immunoassay
S/CO
Abbott Architect
HIV combo
S/CO
Abbott Prism
HIV combo
S/CO
<50 0.05 0.10 0.09
7473 0.32 0.21 0.20
69,101 3.36 1.41 1.11
<50 0.33 0.10 0.07
304 0.09 0.14 0.07
15,280 0.21 0.78 0.44
193,100 1.55 5.46 4.18
<50 0.36 0.07 0.13
12,840 0.60 0.38 0.25
>500,000 12.41 30.84 25.94
<50 0.25 0.11 0.08
197 0.51 0.06 0.07
10,507 0.49 0.28 0.23
173,075 5.671 6.10 4.41
57.3 66.3 64.5 64.5
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Fig. 5. Histogram of digital immunoassay results from 45 HIV-negative samples.
Samples were tested in replicates of 3 with two  reagent and calibrator batches on
different days. The dashed lines a, b, and c depict the mean AEB of the zero calibrator
(0.00559), 4SD from the HIV-negative sample population mean (0.00710), and 3SD
T
Dethod. Samples tested were from four panels of seroconversion samples from HIV
nfected individuals. Digital immunoassay data depicted are the mean of three repli-
ates. bDNA data are as reported by the commercial sample vendor (Zeptometrix).
f the infection (197 RNA copies/mL). The digital p24 assay also
etected the infection in this blood draw, measuring 13.7 fg/mL
24. First detection of this infection by conventional immunoassay
ame 2–3 weeks later.
Table 2 summarizes earliest detection data across six additional
ets of seroconversion samples for the digital immunoassay, three
AT methods, and two conventional immunoassay methods reac-
ive for p24. The digital immunoassay and NAT methods detected
he presence of infection approximately 9–11 days earlier than the
onventional immunoassay methods. The time-to-detection for the
igital immunoassay (20.5 days) was within the range reported
or the NAT methods (18.8–21.3 days). Taken together, these data
ndicate that the digital immunoassay is able to detect acute HIV
nfection with the sensitivity of NAT.
.4. Correlation between p24 and quantitative NAT
A comparison between the digital p24 immunoassay and a
uantitative NAT method across four sets of seroconversion pan-
ls (Table 1) is depicted in Fig. 4. The two methods exhibited
xcellent correlation (R2 0.99). The relationship between measured
24 and RNA copies/mL reported for the bDNA method differed
y approximately 3.5-fold from that obtained by testing a stan-
ardized preparation of cultured virus (Fig. 3). In that study, the
ultured virus was standardized for HIV-1 RNA/mL by the Roche
MPLICOR® HIV-1 MonitorTM Assay, v. 1.5, and the standardiza-
ion was conﬁrmed in the digital immunoassay by agreement with
he accepted stoichiometry of p24 molecules to virus. The NAT data
able 2
ays of initial detection of HIV infection since ﬁrst draw.
HIV infected
donor
Seroconversion
panel designation
Digital p24
immunoassay
Seracare data
Roche CAP/
CTM v1.0 NAAT
S
N
5 PRB968 15 15 1
6  PRB956 40 40 4
7  PBR958 2 0 
8  PBR967 0 3 
9 PBR969 55 55 5
10  PBR972 11 0 1
Mean  days 20.5 18.8 2from the mean zero calibrator signal (0.00781) respectively. The LoD estimated at
0.00781 AEB corresponds to 5.75 fg/mL p24.
in Fig. 4 were as reported by the sample vendor, and details around
the testing were not available. The results between the two meth-
ods demonstrated linear proportionality across a 5-log range, and
the relationship between p24 and RNA copies/mL in this compar-
ison may  reﬂect differences in standardization between the two
NAT methods.
3.5. HIV-negative samples
A preliminary evaluation of HIV-negative samples was con-
ducted on EDTA plasma from 45 presumed normal human donors.
All samples were NAT-negative for HIV RNA (PROCLEIX ULTRIO,
Novartis Diagnostics). Approximately half the samples (24) were
tested with the p24 digital immunoassay using one batch of
reagents and calibrators, and the remaining samples were tested
on a separate date using a second batch of reagents and calibra-
tors. The distribution of immunoassay results from all 45 samples
is depicted in Fig. 5. All but one sample gave an AEB signal below
the mean signal for the zero calibrator (Fig. 5a). A comparison of the
statistics of the HIV-negative samples with the AEB corresponding
to the mean LoD estimated from the zero calibrators (as 3SD above
the zero background) is depicted in Fig. 5b–c. The negative pop-
ulation mean was over four standard deviations lower than the
AEB corresponding to the mean LoD (5.75 fg/mL). Using either cri-
terion (4SD from negative sample mean or estimated LoD) as a
iemens bDNA
AAT
Abbott HIV
RNA NAAT
Perkin Elmer p24
immunoassay
Abbott Architect
HIV combo
immunoassay
5 15 26 26
0 40 47 47
0 0 9 7
7 7 17 17
5 53 63 63
1 3 18 18
1.3 19.7 30.0 29.7
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reliminary cut-off for HIV reactivity, the speciﬁcity of this limited
tudy was 100%.
. Discussion
The data presented in this report demonstrate that by isolat-
ng single labeled immunocomplexes and conﬁning ﬂuorescent
roduct from a brief ampliﬁcation step to a small volume, a
imple immunoassay with a commercially available antibody
air exhibited a 2000–3000-fold reduction in limit of detec-
ion vs. conventional immunoassays reactive for p24 antigen.
his sensitivity improvement, together with the natural 2000-
old ampliﬁcation provided by the p24:virus stoichiometry, enable
mmunoassay sensitivity to virus comparable to NAT for detection
f acute HIV infection. Preliminary analytical LoD was  shown to
e 4.87 fg/mL, approximating 122 RNA copies/mL (∼60 virus/mL).
ithin the sample volume of 100 L utilized for the assay, this
quates to detection of only six viruses. For comparison, commer-
ially available 4th generation HIV combo assays exhibit LoDs of
pproximately 11–70 pg/mL (11,000–70,000 fg/mL) (Fiebig et al.,
003). Across 10 sets of seroconversion samples from HIV infected
ndividuals, the digital immunoassay matched NAT for early detec-
ion of HIV.
A low-cost, easily deployable alternative to NAT could have
mportant implications for HIV screening economics and efﬁcacy.
AT economics in different screening settings is a key issue,
rompting many cost-effectiveness examinations (Stramer et al.,
004; Marshall et al., 2004; Jackson et al., 2003; Custer et al.,
005; Stekler et al., 2009; Hutchinson et al., 2010; Laperche, 2005;
kiaby et al., 2010). In blood bank screening, despite donor pool-
ng to reduce cost, NAT is cost ineffective for serology-negative
etection of acute HIV infection. In the US, estimates of cost
er Quality Adjusted Life Year (QALY) range from $1.5–4.3 mil-
ion unadjusted for inﬂation (Marshall et al., 2004; Jackson et al.,
003) which greatly exceeds normal medical standards (gen-
rally $100,000–200,000 USD (Hutchinson et al., 2010)). Overall
ost effectiveness ratios improve with the inclusion of additional
Fig. 6. Revised HIV screening algorithm proposed by the Center for D
dapted from Rollins (2010).Methods 188 (2013) 153– 160
pathogens (e.g. HIV/HBV/HCV triplex and West Nile virus), and
public expectation of maximum blood safety has led to the estab-
lishment of NAT for blood bank screening in higher income
countries despite its cost. This is not the case, however, for many
European and developing countries (Laperche, 2005; Ekiaby et al.,
2010), where feasibility studies weigh cost effectiveness, infra-
structure requirements, affordability, and disease prevalence vs.
less sensitive alternatives. The practicality of extending NAT pool-
ing to clinical screening has also been explored. Stekler et al. and
Hutchinson et al. concluded that with regular 3rd generation anti-
HIV antibody testing, NAT for acute HIV infection detection makes
sense only in higher risk settings such as sexually transmitted dis-
ease clinics (Stekler et al., 2009; Hutchinson et al., 2010).
Economics aside, timely detection and reporting represent
another challenge limiting the potential epidemiological impact of
NAT detection of acute HIV infection. The acute phase represents
a period of high viremia and hyperinfectiousness, contributing
disproportionately to the spread of the disease (Wawer et al.,
2005; Gray et al., 2001). Turnaround time for executing a pool-
ing strategy, testing, and deconvolution of a positive pool can delay
reporting an acute infection for days, making timely intercession
of a patient’s potential to transmit virus difﬁcult. The time spent
determining a positive result and locating the infected individ-
ual may  largely negate the sensitivity advantage gained by NAT. If
the method by which early stage infection is caught were capable
of a short, patient-speciﬁc turnaround of results, the reduction of
the detection window could have greater practical signiﬁcance, as
there would be greater likelihood of conveying acute HIV infection
status to the patient and preventing further transmission dur-
ing the hyperinfectious stage. Today’s automated high-sensitivity
immunoassays typically have an assay time of an hour or less,
and results can be turned around while the patient waits. By
infusing sample with antibody-coated microbeads, even extremely
low abundance antigen can be quickly and efﬁciently captured
and labeled with good ELISA-grade antibodies. This kinetic prin-
ciple was  recently shown to apply to a very high sensitivity
Simoa digital immunoassay (Chang et al., 2012). Additionally, with
isease Control at the APHL HIV Diagnostics Conference, 2010.
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mmunoassay, virus detection does not require sample pretreat-
ent during early stage infection when competing antibodies are
eak or absent, further enabling a short turnaround time.
While studies on the practicality of NAT in the clinical set-
ing have focused on immunoassay-negative samples, recent HIV
creening recommendations utilize NAT in a conﬁrmatory capacity
Owen et al., 2008; Rollins, 2010). Expanded screening is aimed
t the 20% of HIV infected individuals unaware of the HIV sta-
us (Marks et al., 2006), and a recent algorithm proposed in the
.S. by the Centers for Disease Control (modeled on Western Euro-
ean practice for the past decade) starts with a 4th generation HIV
ombo immunoassay (Fig. 6). A premise of the algorithm is to uti-
ize 4th generation immunoassay screening due to its reactivity
o sufﬁciently elevated p24 prior to seroconversion (Hecht et al.,
002) as well as anti-p24 immunoglobulins following seroconver-
ion. Fig. 6 represents inclusion of acute HIV infection detection
apability to assay point-of-entry testing for clinical HIV screening.
ecause HIV combo immunoassays do not discriminate between
ossible sources of a reactive result, additional discrimination
eﬂex testing is recommended. Ideally, a screening test should offer
hree things: high sensitivity for both acute and chronic infection,
ow cost, and short turnaround time to facilitate patient inter-
ention. NAT provides the highest sensitivity for acute, but can
iss chronic infection when viral load is undetectable. Laboratory
mmunoassays and point-of-care devices offer cost and turnaround
ime advantages, but can miss acute infection. 4th generation
ombo immunoassays have presented the best trade-off among
hese imperatives. Although 4th generation combo immunoassays
horten the detection window relative to serological tests, a sen-
itivity gap remains: patients given a clean bill by 4th generation
mmunoassay may  actually be highly infectious. Failure to diag-
ose acute HIV infection represents a key public health problem
Pao et al., 2005; Brenner et al., 2007). Assured by apparent HIV
egative status, acutely infected individuals represent a high trans-
ission risk and a lost opportunity to control the spread of the virus.
10% of the 300–400 annual HIV infection diagnoses in Seattle, for
xample, were of acute HIV infection (Stekler et al., 2009). A simple
mmunoassay with rapid turnaround time that is capable NAT sen-
itivity for acute HIV infection could represent another step toward
eak-proof HIV screening in a more cost and clinically effective way.
Because of their relative simplicity, immunoassays are more
ractically deployable than NAT in diverse environments. HIV
creening in developing countries and low-resource settings with
igh HIV incidence faces the issues described above, but on a larger,
ore urgent scale. NAT is a sophisticated technology with adop-
ion barriers on both supplier and user sides. Although screening
onated blood with NAT has been in practice since the late 90s,
0% of worldwide blood donations remain unscreened or screened
y less sensitive immunoassay (Global blood safety and availability
HO fact sheet, 2009; Editorial, 2007), and 5–10% of new HIV infec-
ions are transfusion-borne (Busch et al., 2005). In South Africa, the
revalence of HIV infection in the general population is almost 11%
AVERT, 2011), but diagnosis of acute HIV infection is rare (Stevens
t al., 2005). Since NAT is the only methodology currently capa-
le of deﬁnitively diagnosing acute HIV infection, feasibility of NAT
mplementation in these very high incidence settings has been
xamined (Stevens et al., 2005; Karim et al., 2007). Karim et al.
emonstrated the clinical beneﬁt of a pooling strategy for identify-
ng acute HIV infection in a high-risk cohort in South Africa (Karim
t al., 2007). A similar study on patients attending primary health-
are clinics in Johannesburg showed nearly 1% of individuals were
cutely infected, translating to an annual incidence rate of 12.9%
Gous et al., 2010). Gous and colleagues reported 4 cases of acute
IV infection missed by 4th generation immunoassay testing of
005 samples in a Johannesburg general hospital. The pooling strat-
gy spread a $21,568 USD cost for 211 NAT results across the 3005Methods 188 (2013) 153– 160 159
specimens, adding $7.16/specimen to the initial immunoassay cost
(Gous et al., 2010). These studies highlight both the epidemiological
beneﬁts of NAT-sensitive screening for acute HIV infection, as well
as the challenges and economic pressures around NAT adoption.
A low cost immunoassay with the sensitivity of NAT could repre-
sent an opportunity to further impact the spread of transmitted and
transfusion-borne HIV in lower resource, high-risk areas.
The prototype digital p24 immunoassay described in this report
utilizes standard low cost bead-based ELISA reagents and com-
mercially available antibodies. Array technology readily lends to
multiplexing, and from a reagent standpoint, the cost/test for a
‘combo’ digital p24/HIV-1/2 antibody assay would be expected to
be comparable to conventional HIV combo immunoassays – cur-
rently one-third to one-tenth the cost of NAT (Karris et al., 2012).
For low cost automation and deployment of digital immunoas-
says, Kan et al. recently reported proof of principle of low cost
plastic disposable disks composed of 24 ﬂow cells that integrate
microﬂuidics with high-density Simoa microarrays of 216,000-fL
sized wells (Kan et al., 2011). This array disk consumable is aimed
at enabling cost-effective integration of Simoa technology with
conventional automated immunoassay instrumentation perform-
ing paramagnetic bead-based assays. More extensive validation of
the digital p24 immunoassay described and further development
of a high-throughput automated analyzer instrument is ongoing.
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